News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors
Enes Erul/X
May 9, 2024, 00:21

Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors

Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X:

“Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types.”

Enes Erul Enes Erul

Source: Enes Erul/X
cancer Cancer research cancer therapy clinical trial Enes Erul heavily treated patients HER2-mutant Medical Research objective response rate OncoDaily Oncology published study Research safety profile solid tumors Trastuzumab deruxtecan
Special Coverage
Blog
Nov 21, 2024, 06:27
Julie Gralow: Comprehensive Genomic Profiling Improves Precision Therapy Use And Patient Survival
Insight
Nov 20, 2024, 20:44
Baris Turkbey: Excited to announce NCI Molecular Imaging members presenting their research at RSNA2024
Blog
Nov 20, 2024, 20:38
Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
Insight
Nov 20, 2024, 19:12
Nareg Varjabedian: Antidiabetic Drugs and Cancer Prevention
Insight
Nov 20, 2024, 19:12
Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer
Insight
Nov 20, 2024, 19:12
Physicians’ perspectives on cancer-related fatigue management: A cross-sectional survey study in Germany - MASCC
Insight
Nov 20, 2024, 19:12
Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.